RaySearch Laboratories AB Class B released its earnings results on May 09, 2025. The company reported $0.173 earnings per share for the quarter, beating the consensus estimate of $0.119 by $0.054.

Is RaySearch Laboratories AB Class B overvalued?

According to Wall Street analysts RaySearch Laboratories AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does RaySearch Laboratories AB Class B pay dividends?

RaySearch Laboratories AB Class B pays a Annually dividend of $0.315 which represents an annual dividend yield of 0.98%. See more information on RaySearch Laboratories AB Class B dividends here

What is RaySearch Laboratories AB Class B’s EPS estimate?

RaySearch Laboratories AB Class B’s EPS estimate is 0.13.

How many shares outstanding does RaySearch Laboratories AB Class B have?

RaySearch Laboratories AB Class B has 28,627,798 shares outstanding.

What happened to RaySearch Laboratories AB Class B’s price movement after its last earnings report?

RaySearch Laboratories AB Class B reported an EPS of $0.173 in its last earnings report, beating expectations of $0.119. Following the earnings report the stock price went up 30.467%.

Which hedge fund is a major shareholder of RaySearch Laboratories AB Class B?

Currently, no hedge funds are holding shares in RSLBF

Company Description

RaySearch Laboratories AB Class B

RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.

RSLBF Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

RaySearch had a strong Q3 2024 with record-breaking sales and improved operating profit and margin. Key strategic milestones were achieved, such as RayCare's integration with Varian TrueBeam. Despite these successes, there were some challenges, including a decrease in support order intake and lower cash flow from operations. However, the overall sentiment of the call indicates a positive outlook for future growth, supported by increased financial targets.Read More>